is a privately held clinical stage biotech company based in Darmstadt, Germany.
The Company focuses on disorders linked to the enzyme family of transglutaminases
Zedira’s business model
is focused on the development of small molecule drug candidates for early licensing.
Zedira’s drug candidate
for celiac disease therapy, tissue transglutaminase (TG2) blocker ZED1227
is currently tested in phase Ib clinical trials
is licensed to Dr. Falk Pharma for Europe. Dr. Falk Pharma took over responsibility for preclinical and clinical development as well as for approval and marketing of the drug.
Zedira now taps the potential of ZED1227 to address additional indications where dysregulated tissue transglutaminase (TG2) activity is targeted, especially fibrotic disorders (e.g. diabetic nephropathy).
Current development work focuses on safe anticoagulation (thromboprophylaxis)
by coagulation FXIIIa blockers
(F13a, plasma transglutaminase). This novel approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs.
In a rabbit animal model, Zedira
already showed the proof-of-principle of “safe” anticoagulation therapy by inhibition of Factor XIIIa
The Company’s management is open to considering investment by private individuals and institutions.
Please do not hesitate to contact us if you are interested in an attractive opportunity.Zedira
’s managing partners, Dr. Martin Hils and Dr. Ralf Pasternack, will be pleased to be at your disposal: